Some colleagues and I just returned from the NanoBusiness Alliance’s annual conference in Chicago. We offer some quick thoughts from listening to speakers and pass on some anecdotes:
- What is the value of patenting? Should patents only be filed and pursued for actual products? Do they facilitate an exit strategy for a nanotech startup? What to do with existing patents and filings for which the technology is on a "back-burner." These are difficult issues to quantitate. However, one person provided some inside context about a nanotech company that had been purchased by a large, US-based company. The nanotech company was primarily bought for the patents and for blocking others in the market. So persons need to be very careful on valuation issues when they propose to cut spending on patents to only cover existing products.
- Altair Nanotechnologies: recently in a $50M deal, effectively "sold to China"? Is this how the next several decades will flow?
-
US leadership in nanotech not enough if limited to R&D leadership. Is there anything new here? I lived in Japan in 1992-1993, and recall all the discussions in the 80′s and 90′s about our R&D being economically exploited abroad. One new factor, of course: the emergence of S. Korea and China.
-
George Thompson, Intel, has some of the most interesting comments on the history of innovation and nanotech in the context of that history. See his web video at the NNI update meeting this summer (www.nano.gov). China and India led the world in GDP before the industrial revolution. Trending now? The invention of the transistor was not an accident: resulted from a methodical planning. Where is our cabinet level "secretary of innovation"?
-
Congressman Lipinsky: many things "stuck" in the senate, e.g., SBIR/STTR reauthorization! The president’s current budget does not do enough for nanotech. Spending on nanotech is an investment, not a mere cost.
-
Why can Morton salt charge an 18% premium for salt? IP
-
When President Clinton first proposed the NNI (National Nanotechnology Initiative), he spoke of technologies which take 20 years or more to develop. So why all the urgency in 2000-2010 to make a "fast buck" on nanotech?
-
Recently, a march-in right petition was filed to "crack" a Genzyme patent and expand supply of an important drug. The sense is it could succeed which would have a big impact on our Bayh-Dole system.
In any event, these are just a flavor of the many topics at issue at this conference which are critically important in the NNI’s second decade and nanotech’s future. We will continue to monitor these topics.